Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 19/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26693505 | 0.82 | HCRTR1 (0.45) | HCRTR1CCNKCDK12 | |
| SCHEMBL30744422 | 0.82 | HCRTR1 (0.45) | HCRTR1CCNKCDK12 | |
| SCHEMBL21503414 | 0.82 | HCRTR1 (0.45) | HCRTR1CCNKCDK12 | |
| SCHEMBL17007228 | 0.80 | HCRTR1 (0.69) | HCRTR1 | |
| SCHEMBL21491972 | 0.78 | HCRTR1 (0.44) | HCRTR1CCNKCDK12 | |
| SCHEMBL21491975 | 0.78 | HCRTR1 (0.44) | HCRTR1CCNKCDK12 | |
| SCHEMBL30744401 | 0.78 | HCRTR1 (0.44) | HCRTR1CCNKCDK12 | |
| SCHEMBL28524858 | 0.77 | HCRTR1 (0.43) | HCRTR1HCRTR2CCNKCDK12 | |
| Hydrochloric Acid SCHEMBL21491928 | 0.77 | HCRTR1 (0.43) | HCRTR1CCNKCDK12 | |
| Hydrochloric Acid SCHEMBL21491930 | 0.77 | HCRTR1 (0.43) | HCRTR1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | HCRTR1 4246/4885HCRTR2 4665/4885CCNK 99/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | HCRTR1 4246/4885HCRTR2 4665/4885CCNK 99/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | HCRTR1 4246/4885HCRTR2 4665/4885CCNK 99/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | HCRTR1 4246/4885HCRTR2 4665/4885CCNK 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.